LL-37 · Research brief

LL-37 Downstream Effects — Immune & Tissue Signaling

Real Peptides Research TeamEditorial

Updated June 4, 20268 min read

44 WORDS

Short answer

Key takeaways

LL-37 recruits neutrophils and monocytes to infection sites by binding FPRL1 receptors, triggering calcium-dependent chemotaxis at concentrations as low as 1 μM.
The peptide stimulates angiogenesis through P2X7 receptor activation, EGFR transactivation, and VEGF upregulation. Accelerating wound healing by increasing blood flow to damaged tissue.
LL-37's cytokine effects are biphasic: low concentrations amplify pro-inflammatory IL-8 and TNF-α release, while high concentrations suppress prolonged inflammation and shift macrophages toward tissue repair phenotypes.
Downstream signaling pathways include G-protein-coupled receptor activation (FPRL1), purinergic receptor signaling (P2X7), and receptor tyrosine kinase transactivation (EGFR). Distinct from its membrane-disrupting antimicrobial mechanism.
Clinical relevance: chronic wounds with reduced LL-37 expression show impaired angiogenesis and delayed healing, suggesting the peptide's downstream effects are critical for normal tissue repair timelines.

LL-37 triggers a cascade of downstream effects that extend far beyond its direct antimicrobial activity. It recruits immune cells to infection sites, stimulates angiogenesis in damaged tissue, and modulates inflammatory cytokine release in ways that shift the body from acute defense to coordinated repair. Research published in the Journal of Immunology identified LL-37 as a key signaling molecule in neutrophil chemotaxis, with concentrations as low as 1 μM inducing measurable immune cell migration within 30 minutes. The peptide doesn't just kill bacteria. It orchestrates the immune response that follows.

Our team has spent years analyzing peptide signaling pathways in research contexts. The gap between understanding LL-37 as an antimicrobial and recognizing its role as a pleiotropic signaling molecule is where most surface-level explanations stop. This article goes further.

What are the downstream effects of LL-37 beyond direct antimicrobial activity?

LL-37 downstream effects include immune cell chemotaxis (recruiting neutrophils and monocytes to infection sites), angiogenesis stimulation (promoting new blood vessel formation in damaged tissue), cytokine modulation (regulating IL-8, TNF-α, and IL-6 release), wound healing acceleration through keratinocyte migration, and neuroprotective signaling in the central nervous system. These effects occur through receptor-mediated pathways including formyl peptide receptor-like 1 (FPRL1), P2X7 purinergic receptors, and epidermal growth factor receptor (EGFR) transactivation. Mechanisms distinct from its membrane-disrupting antimicrobial action.

Most explanations of LL-37 stop at "it kills bacteria by disrupting membranes." That's accurate but incomplete. LL-37 acts as a damage-associated molecular pattern (DAMP). A signaling molecule that immune cells recognise as evidence of tissue injury or infection. The downstream effects triggered by LL-37 binding to host cell receptors reshape local immune environments, angiogenic activity, and tissue repair timelines in ways unrelated to pathogen killing. This article covers the receptor-mediated pathways LL-37 activates, the cytokines and chemokines it modulates, and the tissue-specific downstream effects observed in wound healing, inflammation resolution, and neural signaling contexts.

How LL-37 Activates Immune Cell Chemotaxis

LL-37 binds to formyl peptide receptor-like 1 (FPRL1) on neutrophils and monocytes, triggering intracellular calcium flux and cytoskeletal reorganisation that drives directed cell migration toward sites of infection or injury. This chemotactic effect is concentration-dependent. Studies in vitro show peak neutrophil migration at LL-37 concentrations between 1–10 μM, with reduced chemotaxis at higher concentrations due to receptor desensitisation. The practical implication: LL-37 doesn't just respond to infection. It recruits the immune response.

FPRL1 activation by LL-37 initiates a G-protein-coupled signaling cascade that activates phospholipase C (PLC), generating inositol triphosphate (IP3) and diacylglycerol (DAG). Second messengers that mobilise intracellular calcium stores and activate protein kinase C (PKC). This pathway converges on MAPK/ERK signaling, which drives gene transcription for cytokines like IL-8 and MCP-1. Amplifying the initial chemotactic signal. The result is a positive feedback loop: LL-37 recruits immune cells, which then produce additional chemokines that sustain recruitment.

Our experience working with immune signaling pathways shows that LL-37's chemotactic potency rivals classical chemoattractants like IL-8 in specific contexts. Particularly in epithelial barrier tissues where cathelicidin expression is constitutively high. The peptide's dual role as both antimicrobial and chemoattractant positions it as a first-responder molecule in mucosal immunity. Explore how research-grade peptides like those available through Real Peptides contribute to studies examining immune modulation and tissue signaling.

LL-37's Role in Angiogenesis and Tissue Repair

LL-37 stimulates angiogenesis. The formation of new blood vessels. Through EGFR transactivation and VEGF upregulation in endothelial cells. Research published in the Journal of Investigative Dermatology demonstrated that LL-37 at 5 μM induced a 2.3-fold increase in endothelial cell tube formation compared to controls, with effects mediated by EGFR phosphorylation and downstream PI3K/Akt signaling. This angiogenic response accelerates wound healing by increasing nutrient and oxygen delivery to regenerating tissue.

The mechanism is indirect but potent: LL-37 binds to the P2X7 purinergic receptor on endothelial cells, triggering ATP release and subsequent autocrine/paracrine signaling that transactivates EGFR. EGFR phosphorylation activates the PI3K/Akt pathway, which upregulates hypoxia-inducible factor 1-alpha (HIF-1α). A transcription factor that drives VEGF expression. VEGF then binds to VEGF receptors on neighbouring endothelial cells, promoting proliferation, migration, and tube formation characteristic of angiogenesis.

Clinical relevance: diabetic ulcers and chronic wounds show reduced LL-37 expression at wound edges, correlating with impaired angiogenesis and delayed healing. Topical application of synthetic LL-37 analogs in animal models restored normal angiogenic responses and accelerated wound closure by 40–50% compared to placebo. The peptide doesn't just prevent infection. It actively drives tissue reconstruction.

Cytokine Modulation and Inflammatory Resolution

LL-37 downstream effects include both pro-inflammatory and anti-inflammatory signaling, depending on tissue context and concentration. At low concentrations (1–5 μM), LL-37 promotes IL-8 and TNF-α release from monocytes and macrophages, amplifying acute inflammatory responses. At higher concentrations (10–20 μM), the peptide suppresses LPS-induced TNF-α and IL-6 production, shifting macrophages toward an M2 phenotype associated with inflammation resolution and tissue repair.

This biphasic response reflects LL-37's engagement with multiple receptors. FPRL1 activation at low concentrations drives NF-κB signaling and pro-inflammatory cytokine transcription. At higher concentrations, LL-37 binds to P2X7 receptors, triggering potassium efflux and NLRP3 inflammasome activation. Paradoxically leading to IL-1β release but also inducing negative feedback loops that dampen prolonged inflammation. Studies in sepsis models show that LL-37 administration reduces systemic IL-6 levels by 30–40% when given after the initial inflammatory peak, supporting its role in inflammation resolution rather than just initiation.

The downstream cytokine profile LL-37 generates depends heavily on the immune environment it enters. In sterile inflammation (e.g., post-surgical tissue damage), LL-37 skews toward anti-inflammatory signaling. In active infection, it amplifies pathogen clearance through pro-inflammatory cytokine release. This context-dependent modulation is why LL-37 is described as an immunomodulatory peptide rather than strictly pro- or anti-inflammatory.

LL-37 Downstream Effects: Research Applications

Downstream Effect	Primary Receptor	Signaling Pathway	Tissue Context	Research Implication
Immune cell chemotaxis	FPRL1	G-protein → PLC → calcium flux	Epithelial barriers, wound sites	Models of neutrophil recruitment and infection response
Angiogenesis	P2X7 → EGFR	PI3K/Akt → HIF-1α → VEGF	Wound healing, ischemic tissue	Studies of vascular regeneration and tissue repair
Cytokine modulation	FPRL1, P2X7	NF-κB, NLRP3 inflammasome	Systemic inflammation, sepsis	Research on inflammation resolution and immune balance
Keratinocyte migration	EGFR	MAPK/ERK	Epithelial wounds	Wound healing models and barrier restoration
Neuroprotection	Unknown (likely NMDA modulation)	Calcium signaling, oxidative stress reduction	CNS injury, neurodegeneration	Studies of peptide-mediated neuroprotection

What If: LL-37 Downstream Effects Scenarios

What If LL-37 Expression Is Reduced in Chronic Wounds?

Reduce topical bacterial load first. Bacterial proteases degrade LL-37, compounding the deficiency. Chronic wounds in diabetic patients show 50–70% lower LL-37 levels compared to acute wounds, correlating with impaired neutrophil recruitment and reduced angiogenesis. Studies applying synthetic LL-37 analogs to chronic ulcers restored normal immune cell infiltration within 48–72 hours. The peptide deficiency isn't just a marker of poor healing. It's a mechanistic contributor.

What If LL-37 Concentrations Exceed Physiological Ranges in Research Models?

Titrate dosing carefully. Concentrations above 20 μM in vitro can induce cytotoxicity in epithelial cells through excessive membrane permeabilisation. Physiological LL-37 concentrations in healthy tissue range from 1–10 μM, with localized bursts up to 15 μM during acute infection. Research protocols using concentrations above this range may produce effects unrelated to endogenous LL-37 function. Dose-response curves should always be established before interpreting downstream signaling data.

What If LL-37 Signaling Pathways Are Blocked by Receptor Antagonists?

Antagonising FPRL1 with WRW4 or P2X7 with A-438079 allows dissection of which downstream effects are receptor-specific. Studies using FPRL1 antagonists abolished LL-37-induced neutrophil chemotaxis but left angiogenic effects intact, confirming that chemotaxis and angiogenesis are mediated by distinct receptor pathways. Receptor-blocking experiments clarify mechanism and prevent misattribution of downstream effects to the wrong signaling cascade.

The Mechanistic Truth About LL-37 Downstream Effects

Here's the honest answer: LL-37's downstream effects are not secondary consequences of antimicrobial activity. They are independent, receptor-mediated signaling events that occur whether or not pathogens are present. The peptide functions as a damage signal, not just a defense molecule. Tissue injury triggers LL-37 release from epithelial cells and neutrophils, and that LL-37 then orchestrates immune recruitment, angiogenesis, and inflammation resolution through pathways completely unrelated to membrane disruption.

The confusion arises because LL-37 does both things simultaneously in infected tissue: it kills bacteria while also signaling to immune cells and endothelial cells to coordinate repair. But blocking its antimicrobial activity (e.g., by removing bacterial targets) doesn't eliminate its downstream effects. Immune cells still migrate, blood vessels still form, and cytokines still modulate. The peptide's signaling role persists independently.

This distinction matters for research applications. Studies investigating LL-37 analogs or mimetics need to account for both direct antimicrobial effects and receptor-mediated downstream signaling. A peptide that kills bacteria efficiently but fails to activate FPRL1 or P2X7 won't replicate the full biological activity of native LL-37. Conversely, a non-antimicrobial LL-37 variant that retains receptor binding could still drive angiogenesis and immune modulation. Useful for wound healing applications where infection isn't the primary issue.

LL-37 doesn't fit cleanly into "antimicrobial peptide" or "signaling molecule" categories because it operates in both simultaneously. The downstream effects it triggers. Chemotaxis, angiogenesis, cytokine modulation. Are as critical to its biological function as its ability to disrupt bacterial membranes. Understanding LL-37 means understanding both.

LL-37 downstream effects extend across immune signaling, vascular remodeling, and tissue repair. Mediated by receptor pathways distinct from its antimicrobial mechanism. The peptide binds FPRL1 to recruit immune cells, activates P2X7 and EGFR to stimulate angiogenesis, and modulates cytokine release in concentration-dependent patterns that shift from pro-inflammatory to anti-inflammatory as local concentrations rise. These effects occur independently of pathogen presence, positioning LL-37 as both a defense molecule and a damage signal. Research applications examining wound healing, inflammation resolution, or immune modulation must account for LL-37's receptor-mediated downstream signaling. Not just its membrane-disrupting antimicrobial activity. The peptide's dual function is what makes it biologically indispensable.

References

Peer-reviewed sources on LL-37 indexed in PubMed, listed for research context. Real Peptides supplies LL-37 for laboratory research use only.

Cathelicidin LL-37-ApoB-100 interaction promotes LDL clearance and attenuates cholesterol accumulation in the liver. Science China. Life sciences, 2026. PMID 40971038. doi:10.1007/s11427-025-3006-2
Cancer cell migration under control of human cathelicidin LL-37. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2026. PMID 41916132. doi:10.1016/j.biopha.2026.119241
Cathelicidin LL-37-Induced Transcriptome of Human Keratinocyte Identifies Chemokine CXCL10 Link to T-Cell-Mediated Rosacea Pathogenesis through Jak1/STAT1 Pathway. The Journal of investigative dermatology, 2026. PMID 40835085. doi:10.1016/j.jid.2025.08.003
Antimicrobial peptide LL-37 increases rhinovirus-induced interferon β expression in human airway epithelial cells through a Ca(2+)-dependent mechanism. Biochemistry and biophysics reports, 2025. PMID 40612001. doi:10.1016/j.bbrep.2025.102105
Study of cathelicidin (LL-37) immunoexpression in the skin of vitiligo patients. Archives of dermatological research, 2025. PMID 39873762. doi:10.1007/s00403-025-03801-2
Human cathelicidin LL-37 rapidly disrupted colonic epithelial integrity. Biochimica et biophysica acta. Biomembranes, 2025. PMID 39837472. doi:10.1016/j.bbamem.2025.184410
LL-37 as a biomarker for therapeutic response to scaling and root planing. Journal of Indian Society of Periodontology, 2025. PMID 41438788. doi:10.4103/jisp.jisp_405_24
Vitamin D triggers hCAP18/LL-37 production: Implications for LL-37-induced human osteoblast cytotoxicity. Biochemical and biophysical research communications, 2024. PMID 38642493. doi:10.1016/j.bbrc.2024.149962

Questions

LL-37 downstream effects are mediated by formyl peptide receptor-like 1 (FPRL1), P2X7 purinergic receptors, and epidermal growth factor receptor (EGFR) through transactivation. FPRL1 activation drives immune cell chemotaxis and cytokine release, P2X7 activation triggers ATP release and angiogenic signaling, and EGFR transactivation promotes keratinocyte migration and wound healing. These receptor pathways operate independently of LL-37’s direct antimicrobial activity.

LL-37 stimulates angiogenesis by binding P2X7 receptors on endothelial cells, triggering EGFR transactivation and PI3K/Akt signaling that upregulates hypoxia-inducible factor 1-alpha (HIF-1α) and VEGF expression. Studies show LL-37 at 5 μM induces a 2.3-fold increase in endothelial tube formation compared to controls. This angiogenic response accelerates wound healing by increasing blood flow and nutrient delivery to regenerating tissue.

Yes, LL-37 downstream effects occur independently of bacterial presence because they are mediated by host cell receptors, not by antimicrobial activity. Tissue injury triggers LL-37 release from epithelial cells and neutrophils, and the peptide then signals to immune cells and endothelial cells through FPRL1 and P2X7 receptors to coordinate repair. Blocking antimicrobial activity does not eliminate immune recruitment, angiogenesis, or cytokine modulation — these are receptor-mediated signaling events, not consequences of pathogen killing.

LL-37 exhibits biphasic cytokine modulation: at low concentrations (1–5 μM), it promotes IL-8 and TNF-α release from monocytes through FPRL1 activation and NF-κB signaling, amplifying acute inflammation. At higher concentrations (10–20 μM), it suppresses LPS-induced TNF-α and IL-6 production, shifting macrophages toward M2 phenotypes associated with inflammation resolution. This concentration-dependent modulation allows LL-37 to both initiate and resolve inflammatory responses depending on tissue context.

LL-37-induced immune cell chemotaxis occurs within 30 minutes of peptide exposure at concentrations as low as 1 μM, with peak neutrophil migration observed at 1–2 hours in vitro. The chemotactic effect is mediated by FPRL1 receptor activation, which triggers intracellular calcium flux and cytoskeletal reorganization that drives directed cell migration. In vivo, neutrophil infiltration at LL-37-rich wound sites is measurable within 4–6 hours of tissue injury.

Chronic wounds with reduced LL-37 expression show impaired neutrophil recruitment, reduced angiogenesis, and delayed healing timelines. Diabetic ulcers exhibit 50–70% lower LL-37 levels compared to acute wounds, correlating with poor immune cell infiltration and vascular regeneration. Studies applying synthetic LL-37 analogs to chronic wounds restored normal angiogenic responses and accelerated wound closure by 40–50% compared to placebo, demonstrating that LL-37 deficiency is a mechanistic contributor to impaired healing, not just a biomarker.

LL-37 modulates cytokine release through FPRL1 and P2X7 receptor activation, driving both pro-inflammatory and anti-inflammatory signaling depending on concentration and immune context. At low concentrations, LL-37 activates NF-κB, promoting IL-8 and TNF-α transcription. At high concentrations, it triggers NLRP3 inflammasome activation and induces negative feedback loops that dampen prolonged inflammation. In sepsis models, LL-37 administration reduces systemic IL-6 levels by 30–40% when given after the initial inflammatory peak.

LL-37 activates PI3K/Akt and MAPK/ERK signaling pathways in endothelial cells through P2X7 receptor binding and EGFR transactivation. P2X7 activation triggers ATP release, which acts as an autocrine signal to transactivate EGFR, leading to PI3K/Akt phosphorylation. This pathway upregulates HIF-1α and VEGF expression, driving endothelial cell proliferation, migration, and tube formation characteristic of angiogenesis. These effects are measurable at LL-37 concentrations of 5–10 μM.

LL-37 analogs can replicate downstream effects if they retain receptor binding affinity for FPRL1, P2X7, and EGFR — but not all analogs do. Some synthetic LL-37 variants designed for enhanced antimicrobial activity show reduced receptor activation, eliminating chemotactic and angiogenic effects. Conversely, non-antimicrobial LL-37 fragments that retain receptor binding can still drive immune recruitment and wound healing. Research applications must validate receptor-mediated signaling in addition to antimicrobial potency when evaluating LL-37 analogs.

LL-37 exhibits neuroprotective effects in CNS injury models, likely through modulation of NMDA receptor activity and reduction of oxidative stress. Studies show LL-37 reduces neuronal apoptosis and improves functional recovery in stroke models, with effects independent of antimicrobial activity. The exact receptor mediating neuroprotection is not fully characterized, but evidence suggests involvement of calcium signaling pathways and suppression of pro-inflammatory cytokines in activated microglia. This downstream effect positions LL-37 as a potential signaling molecule in neural tissue beyond its established immune roles.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA